Key result
The impact of nesiritide on important clinical end points in acute decompensated heart failure, beyond symptomatic and hemodynamic improvement, remains unknown.
Why the study?
Does nesiritide improve clinical endpoints beyond symptomatic and hemodynamic improvement in patients with acute decompensated heart failure?
Does nesiritide improve clinical endpoints beyond symptomatic and hemodynamic improvement in patients with acute decompensated heart failure?
The impact of nesiritide on important clinical endpoints beyond symptomatic and hemodynamic improvement in acute decompensated heart failure remains unknown.
Answers are grounded in this paper and cite their sources.
Unknown effects of nesiritide on hard endpoints in acute decompensated HF may warrant clinical caution; leaves open need for dedicated outcome trials.
Acute decompensated heart failure is a common clinical problem with associated poor outcomes. Over the last decade, attention to this area has greatly increased, with a focus on medical therapies that may safely offer improvement in acute symptoms and early outcomes. Previous therapies that focused on increased inotropy have generally failed to improve symptoms without adverse consequences. Thus, attention towards vasodilators and natriuretic peptides, such as nesiritide, has increased owing to nesiritide's symptomatic improvement and unique mechanism of improvement in hemodynamics. However, the pathophysiology of acute decompensated heart failure is complex and the impact of nesiritide on important clinical end points, beyond symptomatic and hemodynamic improvement, is unknown.
No takes yet. Share an insight, caveat, or question.
DeWald et al. (2010) conducted a review in Acute decompensated heart failure. Nesiritide was evaluated. The impact of nesiritide on important clinical end points in acute decompensated heart failure, beyond symptomatic and hemodynamic improvement, remains unknown.
Synapse has enriched 10 related papers. Consider them for comparative context: